The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity

The idea, approach, and proof-of-concept of the dock and lock (DNL) method, which has the potential for making a large number of bioactive molecules with multivalency and multifunctionality, are reviewed. The key to the DNL method seems to be the judicious application of a pair of distinct protein d...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-09, Vol.13 (18), p.5586s-5591s
Main Authors: CHANG, Chien-Hsing, ROSSI, Edmund A, GOLDENBERG, David M
Format: Article
Language:English
Subjects:
A-kinase anchoring proteins
Amino Acid Sequence
Animals
Antineoplastic agents
Biological and medical sciences
bispecific antibody
Cyclic AMP-Dependent Protein Kinases - chemistry
Dimerization
Humans
Immunoglobulin Fab Fragments - chemistry
Medical sciences
Models, Molecular
Molecular Sequence Data
multifunctional
multivalent
Pharmacology. Drug treatments
Recombinant Fusion Proteins - chemistry
Sequence Homology, Amino Acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The idea, approach, and proof-of-concept of the dock and lock (DNL) method, which has the potential for making a large number of bioactive molecules with multivalency and multifunctionality, are reviewed. The key to the DNL method seems to be the judicious application of a pair of distinct protein domains that are involved in the natural association between protein kinase A (PKA; cyclic AMP–dependent protein kinase) and A-kinase anchoring proteins. In essence, the dimerization and docking domain found in the regulatory subunit of PKA and the anchoring domain of an interactive A-kinase anchoring protein are each attached to a biological entity, and the resulting derivatives, when combined, readily form a stably tethered complex of a defined composition that fully retains the functions of individual constituents. Initial validation of the DNL method was provided by the successful generation of several trivalent bispecific binding proteins, each consisting of two identical Fab fragments linked site-specifically to a different Fab. The integration of genetic engineering and conjugation chemistry achieved with the DNL method may not only enable the creation of novel human therapeutics but could also provide the promise and challenge for the construction of improved recombinant products over those currently commercialized, including cytokines, vaccines, and monoclonal antibodies.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-07-1217